查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1575543

Eylea 市場：按治療層級、給藥方法、患者類型、最終用戶分類 - 全球預測 2025-2030

Eylea Market by Therapeutic Class (Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Disorders), Mode Of Administration (Intravitreal Injection, Ocular Implants), Patient Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年Eylea市場估值為68.9億美元，預計2024年將達72.5億美元，複合年成長率為6.83%，預計2030年將達到109.5億美元。

Eylea（阿柏西普）在眼科藥品市場主要專注於老齡化黃斑部病變（AMD）、糖尿病黃斑部水腫（DME）、視網膜靜脈阻塞（RVO）等視網膜疾病的治療。這項需求是由對有效治療方法的需求所驅動的，這些治療旨在解決全球老齡化人口和糖尿病患者在管理視力障礙方面未得到滿足的關鍵需求。作為注射治療，Eylea 因其經過驗證的功效和安全性而贏得了信心，並主要被眼科醫生廣泛接受和應用。最終用途包括進行此類治療的診所、醫院和門診服務中心。影響該市場的主要成長要素包括視網膜疾病發病率的增加、藥物配方的持續進步以及人們對眼睛健康的認知不斷提高。最近的潛在商機包括進一步納入聯合治療和擴大適應症以佔領更廣泛的市場。這可以透過旨在提高療效和減少副作用的策略研究夥伴關係和臨床試驗來實現。然而，市場成長面臨限制，例如治療成本高、監管環境嚴格以及生物相似藥和替代療法的競爭加劇，這可能會影響定價和市場佔有率。創新的最佳領域包括增強緩釋性製劑等給藥機制，以提高患者的便利性和依從性。另一個有前景的領域是利用人工智慧和機器學習來提高診斷準確性和個人化治療。市場的本質是動態的，受到科學進步和需要不斷適應的競爭壓力的驅動。公司可以透過專注於競爭較少的新興市場並與醫院和醫療保健提供者形成策略聯盟來更好地定位自己。此外，投資教育行銷宣傳活動可以提高醫療保健提供者和患者對 Eylea 益處的認知，並提高市場滲透率。

主要市場統計
基準年[2023] 68.9億美元
預測年份 [2024] 72.5億美元
預測年份 [2030] 109.5億美元
複合年成長率（%） 6.83%

市場動態：揭示快速發展的 Eylea 市場的關鍵市場洞察

Eylea 市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 新興國家醫療保健基礎設施的擴張提高了 Eylea 治療的可近性
    • 製藥公司之間的合作和夥伴關係，以加速 Eylea 的開發和分銷
    • 全球老年人口的增加導致 Eylea 可治療的視網膜疾病發生率上升
    • 增加對創新眼科解決方案研發活動的投資，以支持 Eylea 市場成長
  • 市場限制因素
    • 患者獲得先進抗 VEGF 療法的機會和負擔能力有限
    • 由於新興生物相似藥的競爭加劇，現有品牌的市場佔有率下降
  • 市場機會
    • 制定病患教育計畫以提高對視網膜疾病管理的了解
    • 利用巨量資料分析進行視網膜疾病的早期發現與監測
    • 推廣居家照護解決方案以提高病患便利性和依從性
  • 市場挑戰
    • 視網膜疾病替代治療方案的競爭對 Eylea市場佔有率的影響
    • 影響 Eylea 在每個地區行銷和分銷的監管和合規挑戰

波特五力：駕馭 Eylea 市場的策略工具

波特的五力框架是了解 Eylea 市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 Eylea 市場的外部影響

外部宏觀環境因素在塑造 Eylea 市場的業績動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解 Eylea 市場的競爭狀況

Eylea 市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 Eylea 市場供應商的績效評估

FPNV 定位矩陣是評估 Eylea 市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製 Eylea 市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，Eylea 市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 擴大新興國家的醫療基礎設施改善獲得 Eylea 治療的機會
      • 製藥公司之間的合作和聯盟加速了 Eylea 的開發和分銷
      • 隨著世界各地人口持續老化，視網膜疾病的發生率不斷增加。艾利亞
      • 增加對創新眼科解決方案研發活動的投資，以支持 Eylea 市場成長
    • 抑制因素
      • 先進抗 VEGF 療法的患者獲取機會和費用有限
      • 由於新興生物相似藥的競爭加劇，現有品牌的市場佔有率正在下降
    • 機會
      • 制定病患教育計畫以提高對視網膜疾病管理的了解
      • 利用巨量資料分析早期發現並監測視網膜疾病
      • 推廣居家照護解決方案，提升病患便利性和依從性
    • 任務
      • 視網膜疾病替代治療方案的競爭影響了 Eylea 的市場佔有率
      • 影響 Eylea 在各個地區行銷和分銷的監管和合規挑戰
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章 Eylea 市集（依治療層級）

  • 老齡化黃斑部病變
  • 糖尿病黃斑部水腫
  • 視網膜疾病

第7章 Eylea 市場管理方式

  • 玻璃體內注射
  • 眼內植入
    • 生物分解性
    • 不可生物分解性

第 8 章 Eylea 市場（依病患類型）

  • 成人用
  • 老年病
  • 小兒科

第 9 章 Eylea 市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 眼科診所

第10章 美洲Eylea市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區Eylea市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲Eylea市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C04F0

The Eylea Market was valued at USD 6.89 billion in 2023, expected to reach USD 7.25 billion in 2024, and is projected to grow at a CAGR of 6.83%, to USD 10.95 billion by 2030.

Eylea (aflibercept) operates within the ophthalmology pharmaceutical market, primarily focusing on treating retinal diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Its necessity stems from the demand for effective therapies that address the significant unmet need for managing vision impairment in the aging global population and among diabetic patients. Applied as an injectable treatment, Eylea has gained trust due to its proven efficacy and safety profile, contributing to its widespread acceptance and application primarily among ophthalmologists. The end-use scope encompasses clinics, hospitals, and ambulatory service centers where such treatments are administered. Key growth factors influencing this market include a growing incidence of retinal diseases, continuous advancements in drug formulations, and expanding awareness about eye health. Recent potential opportunities include its further inclusion in combination therapies and expanding indications to capture wider markets. This could be achieved through strategic research partnerships and clinical trials, aiming to enhance efficacy and reduce side effects. However, market growth faces limitations such as high treatment costs, stringent regulatory scenarios, and increasing competition from biosimilars and alternative therapies which may affect pricing and market share. The best areas for innovation include enhancing delivery mechanisms, like sustained-release formulations, to improve patient convenience and compliance. Another promising area is the use of artificial intelligence and machine learning to improve diagnostic accuracy and treatment personalization. The market's nature is dynamic, driven by scientific advancements and competitive pressures that necessitate continuous adaptation. For businesses, focusing on capturing emerging markets with lower competition and creating strategic alliances with hospitals and healthcare providers can position them favorably. Moreover, investing in educational marketing campaigns can boost market penetration by raising awareness of Eylea's benefits among healthcare providers and patients alike.

KEY MARKET STATISTICS
Base Year [2023] USD 6.89 billion
Estimated Year [2024] USD 7.25 billion
Forecast Year [2030] USD 10.95 billion
CAGR (%) 6.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Eylea Market

The Eylea Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of healthcare infrastructure in emerging economies enhancing accessibility to Eylea treatments
    • Collaborations and partnerships among pharmaceutical companies accelerating development and distribution of Eylea
    • Growing elderly population globally contributing to higher incidence of retinal disorders treatable by Eylea
    • Increased investment in research and development activities for innovative ophthalmic solutions supporting Eylea market growth
  • Market Restraints
    • Limited patient accessibility and affordability of advanced anti-VEGF therapies
    • Increasing competition from emerging biosimilars reducing market share of established brands
  • Market Opportunities
    • Developing patient education programs to enhance understanding of retinal disease management
    • Leveraging big data analytics for early detection and monitoring of retinal conditions
    • Promoting home-based care solutions to increase patient convenience and adherence
  • Market Challenges
    • Competition from alternative treatment options for retinal diseases impacting Eylea's market share
    • Regulatory and compliance challenges affecting the marketing and distribution of Eylea in different regions

Porter's Five Forces: A Strategic Tool for Navigating the Eylea Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Eylea Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Eylea Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Eylea Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Eylea Market

A detailed market share analysis in the Eylea Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Eylea Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Eylea Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Eylea Market

A strategic analysis of the Eylea Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Eylea Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Alexion Pharmaceuticals, Inc., Allergan, Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Eylea Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Disorders.
  • Based on Mode Of Administration, market is studied across Intravitreal Injection and Ocular Implants. The Ocular Implants is further studied across Biodegradable and Non-Biodegradable.
  • Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmic Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of healthcare infrastructure in emerging economies enhancing accessibility to Eylea treatments
      • 5.1.1.2. Collaborations and partnerships among pharmaceutical companies accelerating development and distribution of Eylea
      • 5.1.1.3. Growing elderly population globally contributing to higher incidence of retinal disorders treatable by Eylea
      • 5.1.1.4. Increased investment in research and development activities for innovative ophthalmic solutions supporting Eylea market growth
    • 5.1.2. Restraints
      • 5.1.2.1. Limited patient accessibility and affordability of advanced anti-VEGF therapies
      • 5.1.2.2. Increasing competition from emerging biosimilars reducing market share of established brands
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing patient education programs to enhance understanding of retinal disease management
      • 5.1.3.2. Leveraging big data analytics for early detection and monitoring of retinal conditions
      • 5.1.3.3. Promoting home-based care solutions to increase patient convenience and adherence
    • 5.1.4. Challenges
      • 5.1.4.1. Competition from alternative treatment options for retinal diseases impacting Eylea's market share
      • 5.1.4.2. Regulatory and compliance challenges affecting the marketing and distribution of Eylea in different regions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Eylea Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Age-Related Macular Degeneration
  • 6.3. Diabetic Macular Edema
  • 6.4. Retinal Disorders

7. Eylea Market, by Mode Of Administration

  • 7.1. Introduction
  • 7.2. Intravitreal Injection
  • 7.3. Ocular Implants
    • 7.3.1. Biodegradable
    • 7.3.2. Non-Biodegradable

8. Eylea Market, by Patient Type

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Eylea Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals
  • 9.4. Ophthalmic Clinics

10. Americas Eylea Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Eylea Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Eylea Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alcon Inc.
  • 3. Alexion Pharmaceuticals, Inc.
  • 4. Allergan, Inc.
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. Bayer AG
  • 8. Biogen Inc.
  • 9. Bristol-Myers Squibb Company
  • 10. Eli Lilly and Company
  • 11. Genentech, Inc.
  • 12. GlaxoSmithKline plc
  • 13. Johnson & Johnson
  • 14. Merck & Co., Inc.
  • 15. Novartis International AG
  • 16. Pfizer Inc.
  • 17. Regeneron Pharmaceuticals, Inc.
  • 18. Roche Holding AG
  • 19. Sanofi S.A.
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. EYLEA MARKET RESEARCH PROCESS
  • FIGURE 2. EYLEA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EYLEA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EYLEA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL EYLEA MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL EYLEA MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL EYLEA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL EYLEA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES EYLEA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES EYLEA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EYLEA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. EYLEA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EYLEA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EYLEA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL EYLEA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. EYLEA MARKET DYNAMICS
  • TABLE 7. GLOBAL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL EYLEA MARKET SIZE, BY RETINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL EYLEA MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL EYLEA MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL EYLEA MARKET SIZE, BY NON-BIODEGRADABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL EYLEA MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL EYLEA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL EYLEA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES EYLEA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. EYLEA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. EYLEA MARKET, FPNV POSITIONING MATRIX, 2023